Literature DB >> 19811710

Topical diltiazem hydrochloride and glyceryl trinitrate in the treatment of chronic anal fissure.

Masood Jawaid1, Zubia Masood, Manzar Salim.   

Abstract

OBJECTIVE: To compare the symptomatic relief, healing and side-effects of topical diltiazem (DTZ) and glyceryl trinitrate in the treatment of chronic anal fissure. STUDY
DESIGN: Randomized controlled trial. PLACE AND DURATION OF STUDY: The Surgical Outpatient Department of Civil Hospital, Karachi, from March 2006 to February 2007.
METHODOLOGY: Patients with chronic anal fissure were included in the study and randomized to two groups. One group was administered topical 2% diltiazem hydrochloride and other was given 0.2% glyceryl trinitrate (GTN), perianally twice daily for 8 weeks. Patients with anal fissure due to other diseases like inflammatory bowel disease, malignancy, sexually transmitted diseases, previous treatment with local ointment or surgery; patients who required anal surgery for any concurrent disease like hemorrhoids, pregnant women and patients with significant cardiovascular conditions were excluded. There were four follow-up sessions during the course of treatment. Healing and side-effects were recorded. Analysis was done by SPSS version 10 on intention-to-treat basis. Chi-square was used where appropriate.
RESULTS: Eighty patients with symptomatic chronic anal fissure were included in the study and equally divided into two groups. After 8 weeks of treatment healing occurred in 31 of 40 patients treated with diltiazem and 33 of 40 patients treated with GTN (p = 0.576). There were less side-effects with DTZ (n=13) than with GTN (n=29, p < 0.001]. In particular, headache occurred more commonly with GTN (n=27) than with DTZ (n=9, p < 0.0001).
CONCLUSION: Diltiazem hydrochloride and glyceryl trinitrate were equally effective in healing chronic anal fissure. Diltiazem caused fewer side-effects particularly headache than glyceryl trinitrate ointment. Diltiazem may be the first-line treatment for chemical sphincterotomy for the chronic anal fissure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811710     DOI: 10.2009/JCPSP.614617

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  7 in total

1.  Randomised Prospective Controlled Trial of Topical 2 % Diltiazem Versus Lateral Internal Sphincterotomy for the Treatment of Chronic Fissure in Ano.

Authors:  Rajan Vaithianathan; Senthil Panneerselvam
Journal:  Indian J Surg       Date:  2014-05-11       Impact factor: 0.656

Review 2.  Non surgical therapy for anal fissure.

Authors:  Richard L Nelson; Kathryn Thomas; Jenna Morgan; Abigail Jones
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 3.  A systematic review and meta-analysis of the treatment of anal fissure.

Authors:  R L Nelson; D Manuel; C Gumienny; B Spencer; K Patel; K Schmitt; D Castillo; A Bravo; A Yeboah-Sampong
Journal:  Tech Coloproctol       Date:  2017-08-09       Impact factor: 3.781

4.  Topical diltiazem and glyceryl-trinitrate for chronic anal fissure: A meta-analysis of randomised controlled trials.

Authors:  Edward J Nevins; Venkatesh Kanakala
Journal:  Turk J Surg       Date:  2020-12-29

5.  Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure.

Authors:  Monil Shah; Laura Sandler; Vishwas Rai; Charu Sharma; Lakshmi Raghavan
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

Review 6.  A systematic review and meta-analysis of the efficacy of topical sphincterotomy treatments for anal fissure.

Authors:  James Z Jin; Molly-Olivia Hardy; Hanson Unasa; Melbourne Mauiliu-Wallis; Maree Weston; Andrew Connolly; Primal Parry Singh; Andrew G Hill
Journal:  Int J Colorectal Dis       Date:  2021-10-04       Impact factor: 2.571

7.  Morbidity associated with treatment of chronic anal fissure.

Authors:  Ansar Latif; Anila Ansar; Muhammad Qasim Butt
Journal:  Pak J Med Sci       Date:  2013-09       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.